NEW YORK (GenomeWeb News) – Roche Applied Science has licensed exclusive rights to market systems for real-time cell analysis based on Acea Biosciences’ impedance-based technology, the firms announced today.
The technology is being developed for applications including short-term kinetic analysis and for assays for cell proliferation, cytotoxicity, and cell migration and invasion. According to San Diego-based Acea, its technology offers a label-free system, real-time kinetics, live cell quality control, and high information content.
“After completing our product portfolio in DNA/RNA analysis with 454 and NimbleGen, the Acea technology will be an essential cornerstone to strengthen and further extend our product portfolio in cell analysis,” Manfred Baier, head of Roche Applied Science, said in a statement.
Financial terms of the agreement were not disclosed.